Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772066 | 0.84 | ALDH1A1 (0.42) | CNR2CNR1MAP2K1MAP2K2KDM4E | |
| SCHEMBL23772067 | 0.79 | BRD4 (0.46) | L3MBTL1CNR2CNR1MAP2K1MAP2K2 | |
| SCHEMBL29812644 | 0.78 | MAP2K1 (0.41) | MAP2K1MAP2K2KDM4EBRD4BRD9 | |
| SCHEMBL28341822 | 0.78 | CCNC (0.47) | MAP2K1MAP2K2KDM4EBRD4BRD9 | |
| SCHEMBL23772010 | 0.74 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL29868687 | 0.74 | MAP2K1 (0.41) | ADRA1DCNR2MAP2K1MAP2K2KDM4E | |
| SCHEMBL14213217 | 0.71 | BRD4 (0.38) | L3MBTL1ADRA1DMAP2K1MAP2K2KDM4E | |
| SCHEMBL23772004 | 0.70 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL4049110 | 0.70 | BRD4 (0.39) | L3MBTL1ADRA1DCNR2MAP2K1MAP2K2 | |
| SCHEMBL23772030 | 0.68 | LMNA (0.41) | L3MBTL1KDM4EBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | L3MBTL1 1044/4885ADRA1D 4602/4885CNR2 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.